(Q51830138)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Gabriella Scarlatti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Anna Laura Ross

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Andreas Bråve

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Amapola Manrique

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

1 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

305-316

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

Salvage antiretroviral therapy in HIV infection

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

HIV vaccine research: the way forward

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Trials of vaccine against AIDS to begin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Heterologous prime-boost vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

HIV Vaccines: A Global Perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Post-step modifications for research on HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Report on the AIDS Vaccine 2008 Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Expression of AIDS virus envelope gene in recombinant vaccinia viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA02-06 LB. Recombinant modified Vaccinia virus ankara expressing HIV-1 genes activates NK subset capable of controlling HIN infection in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

NYVAC: a highly attenuated strain of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Attenuated measles virus as a vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA021-02. Replicating measles-SHIV vaccine induces long term preservation of central memory CD4 cells in the gut of vaccinated macaques challenged with SHIV

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

A new generation of animal cell expression vectors based on the Semliki Forest virus replicon

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Sindbis virus: an efficient, broad host range vector for gene expression in animal cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

P19-14. Recombinant alphavirus replicon particles as a platform to evaluate immunogenicity of early transmitted clade C virus envelopes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Replication-defective vector based on a chimpanzee adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Engineered adenovirus serotypes for overcoming anti-vector immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

DNA vaccines: ready for prime time?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA05-01. In vivo electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA05-02. Analysis of DNA compared to Ad5 vaccination, as single and mixed modalities, demonstrates robust induction of cellular immune responses in macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA05-03. Efficacy study of a T-cell-based DNA vaccine delivered by intradermal electrotransfer in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Diversity considerations in HIV-1 vaccine selection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Evolutionary and immunological implications of contemporary HIV-1 variation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Consensus and Ancestral State HIV Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Ancestral and consensus envelope immunogens for HIV-1 subtype C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

The challenge of HIV-1 subtype diversity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Development of a quasispecies of human immunodeficiency virus type 1 in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

1 reference

7 January 2021

Antibody neutralization and escape by HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

P10-07. Extremely rapid degranulation of NK cells activated by HIV-specific antibody dependent cellular cytotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

P04-36. HIV-1-speficic antibody dependant cellular cytotoxicity (ADCC) médiated by primary NK cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA021-04. HIV-1 gp41 envelope MPER mutation altered epitope conformation in lipid and increased sensitivity to 2F5 and 4E10 neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA021-05. Insertion of the HIV-1 gp41 epitopes 2F5 and 4E10 into the membrane-proximal region of the vesicular stomatitis virus glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Structure-based antigen design: a strategy for next generation vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Structure of a V3-containing HIV-1 gp120 core

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

P04-38. Crystal structure of gp120 in complex with the CD4-binding-site antibody b13 suggests precise targeting is needed for neutralization.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

African non human primates infected by SIV - why don't they get sick? Lessons from studies on the early phase of non-pathogenic SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Systems biology of innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA07-02. Adenovirus vectors induce expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

P08-06 LB. A genome-wide association study of host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the STEP trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970069-4

7 January 2021

10.1016/S1473-3099(10)70069-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20417413%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference